At the first evaluation (after 4 cycles of DCT) patients were classified as “responders” (Rs) or “non-responders” (NRs) based on the following criteria (according to the Prostate Cancer Working Group 2 -PCWG2-): (i) increase in metastatic lesions; (ii) increase in prostate-specific antigen (PSA) level; (iii) clinical deterioration. The gene discussed is KLK3; the disease is prostate cancer.